Axsome Therapeutics Inc (AXSM)
74.80
+0.61
(+0.82%)
USD |
NASDAQ |
May 03, 16:00
75.50
+0.70
(+0.94%)
After-Hours: 20:00
Axsome Therapeutics Cash from Operations (Quarterly): -30.36M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -30.36M |
| September 30, 2023 | -53.55M |
| June 30, 2023 | -55.35M |
| March 31, 2023 | -5.821M |
| December 31, 2022 | -27.56M |
| September 30, 2022 | -22.76M |
| June 30, 2022 | -33.54M |
| March 31, 2022 | -32.65M |
| December 31, 2021 | -28.84M |
| September 30, 2021 | -26.78M |
| June 30, 2021 | -25.39M |
| March 31, 2021 | -27.22M |
| December 31, 2020 | -20.55M |
| September 30, 2020 | -15.73M |
| June 30, 2020 | -18.90M |
| March 31, 2020 | -23.27M |
| December 31, 2019 | -17.57M |
| September 30, 2019 | -10.63M |
| Date | Value |
|---|---|
| June 30, 2019 | -8.682M |
| March 31, 2019 | -9.499M |
| December 31, 2018 | -9.794M |
| September 30, 2018 | -5.912M |
| June 30, 2018 | -7.667M |
| March 31, 2018 | -6.680M |
| December 31, 2017 | -6.291M |
| September 30, 2017 | -6.447M |
| June 30, 2017 | -7.097M |
| March 31, 2017 | -6.636M |
| December 31, 2016 | -7.217M |
| September 30, 2016 | -4.802M |
| June 30, 2016 | -5.315M |
| March 31, 2016 | -3.948M |
| December 31, 2015 | -2.251M |
| September 30, 2015 | -1.922M |
| June 30, 2015 | -2.107M |
| March 31, 2015 | -1.159M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-55.35M
Minimum
Jun 2023
-5.821M
Maximum
Mar 2023
-25.53M
Average
-25.39M
Median
Jun 2021
Cash from Operations (Quarterly) Benchmarks
| Krystal Biotech Inc | -7.232M |
| Amgen Inc | 689.00M |
| Vertex Pharmaceuticals Inc | 234.60M |
| Alnylam Pharmaceuticals Inc | -81.52M |
| Catalyst Pharmaceuticals Inc | 55.65M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.007M |
| Cash from Financing (Quarterly) | -0.002M |
| Free Cash Flow | -145.66M |
| Free Cash Flow Per Share (Quarterly) | -0.6414 |
| Free Cash Flow to Equity (Quarterly) | -30.99M |
| Free Cash Flow to Firm (Quarterly) | -29.67M |
| Free Cash Flow Yield | -4.29% |